Safety analysis of self-administered enzyme replacement therapy using data from the Fabry Outcome and Gaucher Outcome Surveys

Abstract Background Fabry disease and Gaucher disease are rare genetic disorders characterized by defective degradation of glycosphingolipids caused by enzymatic deficiencies in α–galactosidase A and β–glucocerebrosidase, respectively, and often require life-long treatment. Treatment options for the...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Shoshana Revel-Vilk, Uma Ramaswami, Guillem Pintos-Morell, Derralynn Hughes, Kathy Nicholls, Ricardo Reisin, Roberto Giugliani, Ozlem Goker-Alpan, Majdolen Istaiti, Aidan Gill, Maurizio Scarpa, Jaco Botha
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	BMC 2025-03-01
Reeks:	Orphanet Journal of Rare Diseases
Onderwerpen:	Enzyme replacement therapy Self-administration Agalsidase alfa Velaglucerase alfa Safety Fabry
Online toegang:	https://doi.org/10.1186/s13023-024-03416-2
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!